ClinicalTrials.gg
CompletedNCT00914693Updated Dec 5, 2014

EU/LA Pearl Index Study - Transdermal Contraceptive Patch

A Phase 3 interventional study of Ethinylestradiol/Gestodene (BAY86-5016) in Contraception, sponsored by Bayer. Completed at 66 sites in 8 countries. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2014-12-05.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,694
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The aim of the present study is to prove efficacy and safety of a new contraceptive patch.

02

Conditions studied

  • Contraception

Keywords

  • Fertility control
  • Contraception
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Requiring
  • Normal cervical smear
  • Smokers not older than 30 years
  • History of regular cyclic menstrual periods

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Obesity (> 30 kg/m2
  • Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape
  • Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
  • Use of other methods than study medication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,694 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Ethinylestradiol/Gestodene (BAY86-5016)

Interventions

  • DrugEthinylestradiol/Gestodene (BAY86-5016)

    Drug pages: Ethinyl Estradiol · Gestodene

    7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen

06

What researchers measure

Primary outcomes

  1. Occurrence of pregnancy

    Time frame: 13 treatment cycles each consisting of 28 days and follow-up period of 14 days

Secondary outcomes

  1. Cervical smear

    Time frame: 13 treatment cycles each consisting of 28 days

  2. Adverse events

    Time frame: 13 treatment cycles each consisting of 28 days

  3. Bleeding pattern and cycle control

    Time frame: 13 treatment cycles each consisting of 28 days

Other outcomes

  1. Treatment compliance

    Time frame: 13 treatment cycles each consisting of 28 days

  2. Subjective assessment of satisfaction with the treatment

    Time frame: 13 treatment cycles each consisting of 28 days

07

Study locations

66 sites
  • Lanus Oeste, Buenos Aires 1824, Argentina
  • San Isidro, Buenos Aires B1642CLN, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1280AEB, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1425ASQ, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1425AWC, Argentina
  • Rosario, Santa Fe 2000, Argentina
  • Ashfield, New South Wales 2031, Australia
  • Adelaide, South Australia 5000, Australia
  • North Adelaide, South Australia 5006, Australia
  • Clayton, Victoria 3168, Australia
  • Nedlands, Western Australia 6009, Australia
  • Temuco, Araucanía 4791348, Chile
  • Santiago, 7510025, Chile
  • Santiago, 8320165, Chile
  • Santiago, 8350488, Chile
  • Temuco, 4790711, Chile
  • Biarritz, 64200, France
  • Montargis, 45200, France
  • Nimes, 30029, France
  • Quetigny, 21800, France
  • REIMS Cedex, 51092, France
  • Saint Germain En Laye, 78100, France
  • Toulouse, 31000, France
  • Frankfurt, Hessen 60590, Germany
  • Aachen, Nordrhein-Westfalen 52072, Germany
  • Köln, Nordrhein-Westfalen 50924, Germany
  • Siegen, Nordrhein-Westfalen 57072, Germany
  • Wuppertal, Nordrhein-Westfalen 42103, Germany
  • Blankenburg, Sachsen-Anhalt 38889, Germany
  • Jessen, Sachsen-Anhalt 06917, Germany
  • Magdeburg, Sachsen-Anhalt 39104, Germany
  • Dippoldiswalde, Sachsen 01744, Germany
  • Dresden, Sachsen 01099, Germany
  • Leipzig, Sachsen 04207, Germany
  • Leipzig, Sachsen 04299, Germany
  • Gera, Thüringen 07545, Germany
  • Berlin, 10247, Germany
  • Berlin, 12587, Germany
  • Berlin, 13507, Germany
  • Francavilla Fontana, Brindisi 72021, Italy
  • Bologna, 40138, Italy
  • Cagliari, 09124, Italy
  • Catanzaro, 88100, Italy
  • Firenze, 50134, Italy
  • Modena, 41124, Italy
  • Palermo, 90127, Italy
  • Pavia, 27100, Italy
  • Perugia, 06156, Italy
  • Pisa, 56126, Italy
  • Siena, 53100, Italy
  • Torreón, Coahuila 27000, Mexico
  • Chihuahua, 31350, Mexico
  • Mexico D.F., 11000, Mexico
  • México D.F., 10700, Mexico
  • México, D.F., 11000, Mexico
  • San Luis Potosí, 78230, Mexico
  • San Fernando, Cádiz 11100, Spain
  • Vigo, Pontevedra 36209, Spain
  • Dos Hermanas, Sevilla 41700, Spain
  • Alava, Vitoria 01004, Spain
  • Barcelona, 08013, Spain
  • Barcelona, 08028, Spain
  • Barcelona, 08035, Spain
  • Lugo, 27002, Spain
  • Pamplona, 31015, Spain
  • Zaragoza, 50001, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2009
First posted
Jun 5, 2009
Start
Apr 2009
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Last update
Dec 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00914693
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 5, 2009
Start date
Apr 2009
Primary completion
Sep 2011
Completion
Sep 2011
Last update
Dec 5, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ethinyl Estradiol · Gestodene

Start the discussion